Publications by authors named "Rovithi E"
Backgorund: This study aimed to explore the relationship between different types of skin cancer and factors such as sun exposure and photoprotection measures in a Greek cohort on the island of Crete.
Methods: This cross-sectional observational study was conducted in the Dermatology Department of the University Hospital in Heraklion, Crete, between January 2019 and January 2024. The study population included consecutive patients diagnosed with basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and malignant melanoma (MM), as well as healthy controls.
Article Synopsis
- The study focuses on a coagulase-negative staphylococcus (CoNS) known for its ability to cause severe skin infections, as assessed in patients at a hospital in Greece over a decade.
- A total of 123 skin specimens reflecting the diversity of infections were analyzed, with hidradenitis suppurativa being the most frequent condition, and many cases also presenting co-infections.
- The majority of patients received effective systemic antibiotic treatments, leading to a 100% cure rate, though some notable antibiotic resistance was found against penicillin and clindamycin.
: Antibiotic (AB) therapy is the first step in managing hidradenitis suppurativa (HS). Knowledge of the local patterns of antimicrobial resistance is paramount for the appropriate selection of antimicrobials. This study aimed to assess the occurrence of antibiotic resistance in patients with HS.
View Article and Find Full Text PDFHidradenitis suppurativa (HS) has been linked with body image (BI) impairment and reduced quality of life (QoL). We sought to evaluate the associations between Cutaneous Body Image Scale (CBIS) and disease severity in HS patients.Between July 2020 and January 2022, a cross-sectional study was carried out including consecutive HS patients above the age of 16 who attended a Tertiary Referral Hospital in Greece.
View Article and Find Full Text PDFBackground: Real-world data in patients with moderate psoriasis treated with apremilast is limited.
Objectives: To evaluate the effectiveness and safety of apremilast in bio-naïve patients with moderate psoriasis in real-world clinical settings.
Methods: This was a 52-week multicenter, observational, prospective study of adult outpatients with moderate psoriasis {[10% < body surface area < 20% or 10 < psoriasis area severity index (PASI) < 20] and 10 < dermatology quality of life index (DLQI) < 20} initiated on apremilast ≤7 days before enrollment.